Keyphrases
Temozolomide
100%
Newly Diagnosed
100%
High-grade Glioma
100%
Phase 1 Clinical Trial
100%
Mebendazole
100%
Confidence Interval
18%
Plasma Parameters
18%
Glioblastoma
18%
High Dose
9%
Median Progression-free Survival
9%
Long-term Safety
9%
Median Overall Survival
9%
Progression-free Survival
9%
Alanine Aminotransferase
9%
Single Center
9%
Kaplan-Meier Analysis
9%
Dose-escalation Study
9%
Malignant Glioma
9%
Anaplastic Glioma
9%
Dose Escalation
9%
Safety Study
9%
Brain Cancer
9%
Concurrent Radiation
9%
Adjuvant Temozolomide
9%
Aspartate Transaminase
9%
Human Use
9%
Anthelmintic Drugs
9%
Medicine and Dentistry
Clinical Trial
100%
Ganglioglioma
100%
Temozolomide
100%
Mebendazole
100%
Glioblastoma
27%
Progression Free Survival
18%
Drug Megadose
9%
Kaplan Meier Method
9%
Overall Survival
9%
Isoprenaline
9%
Alanine Aminotransferase
9%
Brain Cancer
9%
Anthelmintic
9%
Aspartate Aminotransferase
9%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Temozolomide
100%
Glioma
100%
Mebendazole
100%
Glioblastoma
27%
Progression Free Survival
18%
Overall Survival
9%
Isoprenaline
9%
Aspartate Aminotransferase
9%
Alanine Aminotransferase
9%
Brain Cancer
9%
Anthelmintic Agent
9%